Excisional Goniotomy in Latino Patients with Open-Angle Glaucoma: Outcomes Through 24 Months

Figures & data

Table 1 Demographic and Baseline Glaucoma Status of the Study Participants

Subject-Level Variables	n=32
Age (yr), mean (SE)	69.8 (2.6)
Gender, n (%)
Male	11 (34.4)
Female	21 (65.6)
Ethnicity, n (%)
Latino	32 (100)
Eye-Level Variables	n=44 eyes
Diagnosis, n (%)
POAG	37 (84.1)
Pseudoexfoliation OAG	7 (15.9)
Glaucoma severity, n (%)
Mild	12 (27.3)
Moderate	17 (38.6)
Severe	15 (34.1)
Cup-disc ratio, mean (SE)	0.7 (0.25)
Medications at baseline, mean (SE)	1.5 (0.2)
Number of medications at baseline, n (%)
0	14 (31.8)
1	14 (31.8)
2	2 (4.6)
3	10 (22.7)
≥4	4 (9.1)
Prior glaucoma interventions, n (%)
Selective laser trabeculoplasty	2 (4.5)
Trabeculectomy	2 (4.5)
Tube-shunt	3 (6.8)
Study Eye, n (%)
Right Eye	23 (52.3)
Left Eye	21 (47.7)

Table 2 Mean IOP and Changes from Baseline at Each Study Time Point

	All Eyes (N=44)					Baseline IOP < 18 mmHg (N=24)					Baseline IOP ≥ 18 mmHg (N=20)
	n	Mean	Mean Change	Mean % Change	P value*	n	Mean	Mean Change	Mean % Change	P value*	n	Mean	Mean Change	Mean % Change	P value*
Baseline	44	17.8 (0.66)	–	–	–	24	14.8 (0.36)	–	–	–	20	21.3 (0.87)	–	–	–
Day 1	40	16.1 (1.38)	−1.57 (1.47)	−5.47 (8.31)	0.2923	22	14.5 (1.59)	−0.36 (1.66)	−0.69 (10.86)	0.8290	18	18 (2.34)	−3.05 (2.59)	−11.31 (13.03)	0.2537
Week 1	43	15.1 (0.95)	−2.67 (0.99)	−12.24 (5.33)	0.0104	24	14.2 (1.06)	−0.54 (1.06)	−2.96 (6.88)	0.6147	19	16.1 (1.70)	−5.37 (1.64)	−23.95 (7.75)	0.0043
Month 1	42	13.6 (0.81)	−4.19 (1.05)	−19.74 (5.23)	0.0003	23	12.7 (0.79)	−2 (0.86)	−12.37 (5.73)	0.0300	19	14.6 (1.52)	−6.84 (1.93)	−28.67 (9.00)	0.0023
Month 3	31	13.3 (0.66)	−4.58 (0.97)	−22.53 (4.22)	<0.0001	16	12.5 (0.50)	−2.37 (0.56)	−15.29 (3.34)	0.0007	15	14.2 (1.24)	−6.93 (1.75)	−30.26 (7.62)	0.0014
Month 6	37	13.8 (0.52)	−4.22 (0.96)	−18.69 (4.09)	0.0001	20	14 (0.48)	−0.85 (0.60)	−4.54 (3.83)	0.1754	17	13.6 (1)	−8.18 (1.50)	−35.34 (5.42)	<0.0001
Month 12	33	13.3 (0.51)	−4.39 (0.95)	−20.78 (4.19)	<0.0001	18	13.1 (0.66)	−1.44 (0.70)	−9.02 (4.93)	0.0565	15	13.5 (0.82)	−7.93 (1.46)	−34.90 (5.16)	<0.0001
Month 24	32	12.4 (0.51)	−4.31 (0.80)	−23.06 (3.82)	<0.0001	21	12.8 (0.64)	−1.91 (0.56)	−12.98 (3.70)	0.0027	11	11.8 (0.87)	−8.91 (1.19)	−4229 (4.81)	<0.0001

Note: *Significance for mean change from baseline.

Table 3 Mean Medications and Changes from Baseline at Each Study Time Point

	All Eyes (N=44)					Baseline IOP < 18 mmHg (N=24)					Baseline IOP ≥ 18 mmHg (N=20)
	n	Mean	Mean Change	Mean % Change	P value*	n	Mean	Mean Change	Mean % Change	P value*	n	Mean	Mean Change	Mean % Change	P value*
Baseline	44	1.5 (0.22)	–	–	–	24	1.13 (0.20)	–	–	–	20	1.95 (0.41)	–	–	–
Month 1	42	0.26 (0.10)	−1.21 (0.21)	−87.1 (5.51)	<0.0001	24	0.17 (0.10)	−0.96 (0.20)	−90.74 (6.49)	<0.0001	18	0.39 (0.20)	−1.55 (0.40)	−80.67 (10.20)	0.0011
Month 3	32	0.44 (0.15)	−1.06 (0.20)	−82.2 (6.94)	<0.0001	16	0.31 (0.15)	−81 (0.24)	−87.18 (8.88)	0.0047	16	0.56 (0.27)	−1.31 (0.32)	−75.67 (11.20)	0.0011
Month 6	36	0.22 (0.09)	−1.14 (0.21)	−87.2 (5.43)	<0.0001	20	0.15 (0.11)	−0.75 (0.16)	−88.09 (8.27)	0.0002	16	0.31 (0.15)	−1.62 (0.42)	−85.92 (5.82)	0.0014
Month 12	33	0.82 (0.21)	−1 (0.22)	−58.4 (11.9)	<0.0001	18	0.61 (0.23)	−0.78 (0.22)	−59.37 (17.27)	0.0027	15	1.07 (0.37)	−1.27 (0.41)	−56.83 (15.53)	0.0077
Month 24	32	0.97 (0.22)	−0.66 (0.22)	−47.1 (13)	0.0061	21	0.81 (0.24)	−0.43 (0.23)	−46.08 (17.35)	0.0829	11	1.27 (0.45)	−1.09 (0.46)	−49.37 (18.70)	0.0379

Note: *Significance for mean change from baseline.

Table 4 Treatment Success at Each Study Time Point

	All Eyes			Baseline IOP < 18 mmHg			Baseline IOP ≥ 18 mmHg
	IOP Reduction ≥ 20% (%)	Medication Reduction ≥ 1 (%)*		IOP Reduction ≥ 20% (%)	Medication Reduction ≥ 1 (%)*		IOP Reduction ≥ 20% (%)	Medication Reduction ≥ 1 (%)*
Month 1	54.8	26	92.9	39.1	17	94.4	73.7	9	90
Month 3	48.4	21	91.3	31.2	12	92.3	66.7	9	90
Month 6	48.6	22	95.6	20.0	13	92.9	82.3	9	100
Month 12	51.5	22	84.6	27.8	13	81.2	80.0	9	90
Month 24	56.2	18	72.0	33.3	11	64.7	100.0	7	87.5

Note: *Among eyes on ≥1 medication at baseline.

Table 5 Adverse Events

Adverse Event	Incidence, n (%)
Intraocular pressure elevation	8 (18.2)
Corneal edema	4 (9.1)
Cystoid macular edema	1 (2.3)
Posterior capsule opacification	1 (2.3)
Epiretinal membrane	1 (2.3)
Branch retinal vein occlusion	1 (2.3)
Persistent hypotony	1 (2.3)